EBS
Emergent Biosolutions Inc
NYSE: EBS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.33
-4.38% today
Updated 2026-06-05
Market cap
$419.99M
P/E ratio
—
P/S ratio
0.62x
EPS (TTM)
$-0.19
Dividend yield
—
52W range
$6 – $14
Volume
0.7M
Emergent Biosolutions Inc (EBS) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$8.33
12-Month target
$6.47
2030 Target
—
Intrinsic (DCF)
$30.24
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $1.1B | $1.0B | $1.0B | $0.7B | $0.6B | $0.5B | $0.5B | $0.4B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: -13.98% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -1.27%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.